

**Amendments to the Specification:**

Please replace paragraph [0001] with the following amended paragraph:

[0001] The present application is a continuation of U.S. application no. 09/473,653, filed December 29, 1999, now patent no. 6,703,015, which claims benefit under 35 U.S.C. §119(e) of U.S. provisional application no. 60/152,417, filed September 3, 1999.

Please replace paragraph [0071] with the following amended paragraph:

[0071] Figure 25 shows inhibition of serum of ~~an~~-immunized mice in binding to  $\beta$ AP by synthetic peptides derived from the N-terminal of  $\beta$ -amyloid peptide. The assay was done with 1:3000 dilution of serum after a third immunization with f88-EFRH reacted with the various peptides (including, as shown, EFRH (SEQ ID NO:1), DAEFRH (residues 1-6 of SEQ ID NO:3), DAEFRHD (residues 1-7 of SEQ ID NO:8) and DAEFRHDSG (residues 1-9 of SEQ ID NO:3)) in various concentrations per well, as indicated. The peptide WVLD (SEQ ID NO:4) was used as a negative control.